A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies
ConclusionsThe RP2D of sapanisertib in East Asian patients (3 mg QD) was lower than in Western patients (4 mg QD), but the pharmacokinetics and safety profiles were similar. Sapanisertib was well tolerated and showed moderate anti-tumor effects in heavily pretreated patients with nonhematologic malignancies.NCT NumberNCT03370302; Registered December 7, 2017 (Source: Targeted Oncology)
Source: Targeted Oncology - November 29, 2021 Category: Cancer & Oncology Source Type: research
Prognostic Differences of RAS Mutations: Results from the South Australian Metastatic Colorectal Registry
ConclusionsWhilst the G12S mutation was associated with the longest survival numerically, the observed survival for patients with the most common RAS mutations (G12C, G12V, G12A, G12D and G13D) did not significantly differ. (Source: Targeted Oncology)
Source: Targeted Oncology - November 25, 2021 Category: Cancer & Oncology Source Type: research
Retrospective Chart Review of Dabrafenib Plus Trametinib in Patients with Metastatic BRAF V600-Mutant Melanoma Treated in the Individual Patient Program (DESCRIBE Italy)
ConclusionTreatment ofBRAF V600E-mutant metastatic melanoma with dab + tram in the real-world setting was effective and safe, including the unselected population with several patients having a high tumor burden – concordant with the results of the pivotal phase 3 studies of dab + tram. (Source: Targeted Oncology)
Source: Targeted Oncology - November 10, 2021 Category: Cancer & Oncology Source Type: research
Correction to: Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer
(Source: Targeted Oncology)
Source: Targeted Oncology - November 10, 2021 Category: Cancer & Oncology Source Type: research
Thromboembolism in Patients with Metastatic Renal Cell Carcinoma Treated with Immunotherapy
ConclusionsPatients with mRCC treated with IO had a high incidence of TE. TE was associated with risk of treatment delay, hospitalization, and mortality, while TE, IMDC poor risk, and Khorana score ≥ 2 were associated with worse survival. Further investigations into IO-associated TE are needed to identify benefit from primary thromboprophylaxis. (Source: Targeted Oncology)
Source: Targeted Oncology - November 6, 2021 Category: Cancer & Oncology Source Type: research
Durvalumab: A Review in Extensive-Stage SCLC
AbstractDurvalumab (IMFINZI®), a fully human monoclonal antibody against programmed cell death-ligand 1 (PD-L1), is approved for use in combination with etoposide and either carboplatin or cisplatin for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC). In the pivotal phase III CASPIAN trial in previously untreated adults with ES-SCLC, the addition of durvalumab to chemotherapy for up to 4 cycles followed by maintenance durvalumab was associated with a significantly longer overall survival and a favourable hazard ratio for progression-free survival compared with chemotherapy alone ...
Source: Targeted Oncology - November 3, 2021 Category: Cancer & Oncology Source Type: research
Phase II Study of Third-Line Panitumumab Rechallenge in Patients with Metastatic Wild-Type KRAS Colorectal Cancer Who Obtained Clinical Benefit from First-Line Panitumumab-Based Chemotherapy: JACCRO CC-09
ConclusionIrinotecan plus panitumumab rechallenge is a promising third-line treatment regimen in patients with metastatic wild-typeKRAS colorectal cancer.Clinical Trial IdentificationUMIN000015916. (Source: Targeted Oncology)
Source: Targeted Oncology - October 31, 2021 Category: Cancer & Oncology Source Type: research
Association of Tumor Mutational Burden and Immune Gene Expression with Response to PD-1 Blockade by Sasanlimab Across Tumor Types and Routes of Administration
ConclusionsOur findings indicate an active, immunomodulatory mechanism for the anti-PD-1 antibody sasanlimab across different tumor types and routes of administration.Trial RegistrationClinicalTrials.gov identifier NCT02573259; registered October 2015. (Source: Targeted Oncology)
Source: Targeted Oncology - October 25, 2021 Category: Cancer & Oncology Source Type: research
Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
(Source: Targeted Oncology)
Source: Targeted Oncology - October 25, 2021 Category: Cancer & Oncology Source Type: research
Avelumab in Combination Regimens for Relapsed/Refractory DLBCL: Results from the Phase Ib JAVELIN DLBCL Study
ConclusionsThe low level of clinical activity suggests that PD-L1 inhibitor activity may be limited in R/R DLBCL.ClinicalTrials.gov IdentifierNCT02951156. (Source: Targeted Oncology)
Source: Targeted Oncology - October 23, 2021 Category: Cancer & Oncology Source Type: research
Immune Checkpoint Inhibitors for Advanced Cutaneous Squamous Cell Carcinoma: A Systematic Review with Meta-Analysis
ConclusionSurgical treatment of CSCC remains the guideline-based standard of care for curative intent of local, LA, and LR disease. ICIs demonstrate promising results for LA, LR, and R/M CSCC not amenable to surgery. Endpoints assessing survival and durability of response have not been reached, warranting additional trials exploring neoadjuvant or adjuvant therapy in combination with local treatment. (Source: Targeted Oncology)
Source: Targeted Oncology - October 22, 2021 Category: Cancer & Oncology Source Type: research
Acknowledgement to Referees
(Source: Targeted Oncology)
Source: Targeted Oncology - October 22, 2021 Category: Cancer & Oncology Source Type: research
A Real-World Study of Patients with Advanced Non-squamous Non-small Cell Lung Cancer with EGFR Exon 20 Insertion: Clinical Characteristics and Outcomes
ConclusionsThis large national study in nsqNSCLC patients confirms thatEGFR exon 20ins is a rare condition (0.6%). The prognosis associated with exon 20ins appears to be in line with that of wild-typeEGFR, but worse than commonEGFR mutations, highlighting the need for advancements for this rare population. (Source: Targeted Oncology)
Source: Targeted Oncology - October 18, 2021 Category: Cancer & Oncology Source Type: research
Making Treatment-Free Remission (TFR) Easier in Chronic Myeloid Leukemia: Fact-Checking and Practical Management Tools
AbstractIn chronic-phase chronic myeloid leukemia (CML), tyrosine kinase inhibitors (TKIs) are the standard of care, and treatment-free remission (TFR) following the achievement of a stable deep molecular response (DMR) has become, alongside survival, a primary goal for virtually all patients. The GIMEMA CML working party recently suggested that the possibility of achieving TFR cannot be denied to any patient, and proposed specific treatment policies according to the patient ’s age and risk. However, other international recommendations (including 2020 ELN recommendations) are more focused on survival and provide less det...
Source: Targeted Oncology - October 18, 2021 Category: Cancer & Oncology Source Type: research
Correction to: Real-World Tumor Response of Palbociclib Plus Letrozole Versus Letrozole for Metastatic Breast Cancer in US Clinical Practice
(Source: Targeted Oncology)
Source: Targeted Oncology - October 15, 2021 Category: Cancer & Oncology Source Type: research
